Remains preferred provider among biopharmaceutical companies
Quintiles has been named the market leader in Phase IV services for the third year in a row, according to the 2015 CRO Quality Benchmarking – Phase IV Service Providers Report from Industry Standard Research (ISR).
Quintiles was selected as the preferred provider among biopharmaceutical companies for Phase IV services based on a survey of 110 global biopharma representatives. In the report, Quintiles was highlighted as a leader across a number of key service quality metrics, including its service breadth, global footprint and technology that enables real-time data access delivered by its award-winning Quintiles Infosario platform.
Andrea Spannheimer, Senior Vice President, Real-World & Late Phase Research, Quintiles, “We are proud to be honoured once again for our leadership in Phase IV services across all of our customer segments. This acknowledgement reflects our unmatched depth and breadth of expertise, as well as scientific affairs thought leadership and services, which are required to provide the right approach to the right question for our customers worldwide. We especially want to thank our talented employees – this recognition is a testament to their tireless dedication.”
Compared to the other 33 Phase IV contract research organisations noted in the report, Quintiles was a top performer in a number of selection criteria including: leadership, preference, customer loyalty, performance relative to expectations, perceived differentiation of service quality.
Survey participants were decision-makers from small, mid-size and large global biopharma companies and were required to have been involved in outsourced Phase IV trials within the past 18 months.